Cell and Molecular Tissue Engineering, LLC

University of Connecticut

Hoechst Roussel Pharmaceuticals

Donald L Kreutzer

Ulrike W Klueh

David Isaac Dorsky

Fotios Papadimitrakopoulos

Jeffrey T Koberstein

William J Novick, Jr

Diane J Burgess

Samuel Huang

Francis Moussy

Michael P Sheetz

David I Dorsky

Products, systems and methods are disclosed for lowering the concentrations of at least one of preservatives and fibrils in a liquid insulin composition. One method comprises replacing at least a portion of at least one of phenol and m-cresol with at least one of cyclodextrins, cyclodextrin polymers, cyclodextrin beads, and an ion exchange resin.

Systems, methods and products for minimizing tissue reactions and tissue injury at an infusion site

Disclosed herein are medical products, including an implantable device coated with a crosslinked extracellular matrix comprising at least one of Type IV collagen and laminin, wherein the crosslinked extracellular matrix contains no more than 0.024 mg/ml total concentration of glucose, amino acids and salts having a molecular weight of 2000 daltons or less. Corresponding systems and method also are disclosed.

Implantable devices coated with extracellular matrix

Disclosed herein are medical products, including a surgical mesh, with a layer of dehydrated modified basement membrane preparation formed thereon. The basement membrane has been modified before dehydration of remove low molecular weight components. In some embodiments, the basement membrane is crosslinked. Methods of making and using the products also are disclosed.

Coated surgical mesh, and corresponding systems and methods

Disclosed herein are sensors with a layer of dehydrated modified basement membrane preparation formed thereon. The basement membrane has been modified before dehydration of remove low molecular weight components. In some embodiments, the basement membrane is crosslinked. Methods of making and using the products also are disclosed.

Coated sensors, and corresponding systems and methods

Disclosed herein are medical products with a layer of dehydrated modified basement membrane preparation formed thereon. The basement membrane has been modified before dehydration of remove low molecular weight components. Methods of making and using the products also are disclosed.

Sensors, cannulas, collars and coated surgical mesh, and corresponding systems and methods

An implant system and a method for controlling the natural and artificial microenvironments surrounding an implanted device using an artificial tissue system (ATS) and includes methods of diagnostic and testing related thereto. The ATS, among other things, induce better integration, function, and extended lifespan of the devices at the site of implantation. The ATS includes cells, such as naturally occurring, engineered, and/or artificial cells; matrices such as natural, engineered, artificial and/or hybrid matrices; tissue response modifiers (TRM); and/or cell response modifiers (CRM). The specific composition of the ATS is based on the nature of the tissue in which ATS-device combination is implanted and the nature of the implant device, as well as the required function and lifespan of the implanted device. Additionally, the ATS, as well as ATS-device combinations can be utilized in vitro to aid in the design of improved ATS, devices and ATS-device combinations for in vivo uses.

Artificial tissue systems and uses thereof

An implant system and a method for controlling the natural and artificial microenvironments surrounding an implanted device using an artificial tissue system (ATS) and includes methods of diagnostic and testing related thereto. The ATS, among other things, induce better integration, function, and extended lifespan of the devices at the site of implantation. The ATS includes cells, such as naturally occurring, engineered, and/or artificial cells; matrices such as natural, engineered, artificial and/or hybrid matrices; tissue response modifiers (TRM); and/or cell response modifiers (CRM). The specific composition of the ATS is based on the nature of the tissue in which ATS-device combination is implanted and the nature of the implant device, as well as the required function and lifespan of the implanted device. Additionally, the ATS, as well as ATSdevice combinations can be utilized in vitro to aid in the design of improved ATS, devices and ATS-device combinations for in \&#x3e;ivo uses.

A tissue/implant interface, comprising an implant and a bioactive polymer layer adjacent at least a portion of the outer surface of the implant, wherein the polymer layer contains at least one tissue response modifier covalently attached to the polymer layer or entrapped within the polymer layer in a quantity effective to control the tissue response at the site of implantation. Preferably, the at least one tissue response modifier controls inflammation, fibrosis, and/or neovascularization. Exemplary tissue response modifiers include, but are not limited to, steroidal and non-steroidal anti-inflammatory agents, anti-fibrotic agents, anti-proliferative agents, cytokines, cytokine inhibitors, neutralizing antibodies, adhesive ligands, and combinations thereof. Use of the various combinations of tissue response modifiers with bioactive polymers provides a simple, flexible and effective means to control the implant/tissue interphase, improving implant lifetime and function.

Implant coating for control of tissue/implant interactions

A method of enhancing host defense mechanisms utilizing xanthines is disclosed.

Growing community of inventors

Avon, CT, United States of America

Donald L Kreutzer